“Who gets treated for hepatitis C?” is a medical decision for infectious disease specialists, not a question of “ethics, costs or access” for well-meaning executives. “Who pays?” depends on measuring the real social costs of failing to treat a national epidemic and cannot be measured by the limited considerations of private entities and public agencies in a single state, or even several states.
Attorneys filed lawsuits in Pennsylvania and Massachusetts this week on behalf of prisoners who say they’re being denied new lifesaving treatment for Hepatitis C because of the cost of the drugs. Gilead Sciences manufactures two versions of the cure, Harvoni and Sovaldi. Abbvie Pharmaceutical Limited, formerly Abbot Labs, manufactures another, Viekira Pak. The cost of any one of the three is roughly $90,000.